Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibikase Therapeutics (IKT) Non-Current Debt (2020 - 2021)

Inhibikase Therapeutics (IKT) has disclosed Non-Current Debt for 2 consecutive years, with $248911.0 as the latest value for Q2 2021.

  • Quarterly Non-Current Debt changed N/A to $248911.0 in Q2 2021 from the year-ago period, while the trailing twelve-month figure was $248911.0 through Jun 2021, changed N/A year-over-year, with the annual reading at $276461.0 for FY2020, N/A changed from the prior year.
  • Non-Current Debt for Q2 2021 was $248911.0 at Inhibikase Therapeutics, roughly flat from $248911.0 in the prior quarter.
  • The five-year high for Non-Current Debt was $276461.0 in Q4 2020, with the low at $248911.0 in Q1 2021.